• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza

tetano

Editor, Senior Moderator
Vaccine. 2019 Mar 8. pii: S0264-410X(19)30264-6. doi: 10.1016/j.vaccine.2019.02.057. [Epub ahead of print]
[h=1]Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza.[/h] Sekiya T[SUP]1[/SUP], Mifsud EJ[SUP]1[/SUP], Ohno M[SUP]2[/SUP], Nomura N[SUP]2[/SUP], Sasada M[SUP]2[/SUP], Fujikura D[SUP]2[/SUP], Daito T[SUP]2[/SUP], Shingai M[SUP]3[/SUP], Ohara Y[SUP]4[/SUP], Nishimura T[SUP]4[/SUP], Endo M[SUP]4[/SUP], Mitsumata R[SUP]5[/SUP], Ikeda T[SUP]5[/SUP], Hatanaka H[SUP]6[/SUP], Kitayama H[SUP]6[/SUP], Motokawa K[SUP]7[/SUP], Sobue T[SUP]8[/SUP], Suzuki S[SUP]9[/SUP], Itoh Y[SUP]9[/SUP], Brown LE[SUP]10[/SUP], Ogasawara K[SUP]11[/SUP], Kino Y[SUP]12[/SUP], Kida H[SUP]13[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] In contrast to current ether- or detergent-disrupted "split" vaccines (SVs) for influenza, inactivated whole influenza virus particle vaccines (WPVs) retain the original virus structure and components and as such may confer similar immunity to natural infection. In a collaboration between academia and industry, the potential of WPV as a new seasonal influenza vaccine was investigated. Each of the four seasonal influenza vaccine manufacturers in Japan prepared WPVs and SVs from the same batches of purified influenza virus. Both mice and monkeys vaccinated with the WPVs exhibited superior immune responses to those vaccinated with the corresponding SVs. Vaccination with A/California/07/2009 (H1N1) WPV enabled mice to survive a lethal challenge dose of homologous virus whereas those vaccinated with SV succumbed to infection within 6 days. Furthermore, mice vaccinated with WPV induced substantial numbers of multifunctional CD8[SUP]+[/SUP] T cells, important for control of antigenically drifted influenza virus strains. In addition, cytokines and chemokines were detected at early time points in the sera of mice vaccinated with WPV but not in those animals vaccinated with SV. These results indicate that WPVs induce enhanced innate and adaptive immune responses compared to equivalent doses of SVs. Notably, WPV at one fifth of the dose of SV was able to induce potent immunity with limited production of IL-6, one of the pyrogenic cytokines. We thus propose that WPVs with balanced immunogenicity and safety may set a new global standard for seasonal influenza vaccines.
Copyright ? 2019. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] Inactivated whole influenza virus particle vaccine; Seasonal and pandemic influenza

PMID: 30857932 DOI: 10.1016/j.vaccine.2019.02.057
 
Back
Top Bottom